Loading...
XNYS
MDT
Market cap118bUSD
Sep 17, Last price  
92.77USD
1D
0.18%
1Q
16.93%
Jan 2017
30.24%
Name

Medtronic PLC

Chart & performance

D1W1MN
XNYS:MDT chart
P/E
24.74
P/S
3.27
EPS
3.75
Div yield, %
3.05%
Shrs. gr., 5y
-0.68%
Rev. gr., 5y
3.09%
Revenues
36.36b
+8.43%
28,833,000,00028,833,000,00029,710,000,00029,710,000,00029,953,000,00029,953,000,00030,557,000,00030,557,000,00028,913,000,00028,913,000,00030,117,000,00031,686,000,00031,686,000,00031,227,000,00031,227,000,00032,364,000,00032,364,000,00033,537,000,00033,537,000,00036,364,000,000
Net income
4.80b
+2.96%
3,538,000,0003,538,000,0004,028,000,0004,028,000,0003,104,000,0003,104,000,0004,631,000,0004,631,000,0004,789,000,0004,789,000,0003,606,000,0005,039,000,0005,039,000,0003,758,000,0003,758,000,0003,676,000,0003,676,000,0004,662,000,0004,662,000,0004,800,000,000
CFO
7.33b
+4.06%
5,218,000,0005,218,000,0006,880,000,0006,880,000,0004,684,000,0004,684,000,0007,007,000,0007,007,000,0007,234,000,0007,234,000,0006,240,000,0007,346,000,0007,346,000,0006,039,000,0006,039,000,0006,787,000,0006,787,000,0007,044,000,0007,044,000,0007,330,000,000
Dividend
Sep 25, 20260.72 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Related entities

Subsidiaries (35)
Covidien Eurasia LLC
COVIDIEN LP
INDIA MEDTRONIC PRIVATE LIMITED
Medtronic AF Luxembourg S. a r.l.
Medtronic Aktiebolag
Medtronic Global Holdings S.C.A.
MEDTRONIC INTERNATIONAL TRADING PTE. LTD.
MEDTRONIC IP HOLDING INTERNATIONAL LUXEMBOURG SARL
MEDTRONIC KOREA LTD
MEDTRONIC POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
MEDTRONIC SINGAPORE OPERATIONS PTE. LTD.
Medtronic Sweden Finance AB
ARTERIAL VASCULAR ENGINEERING CANADA, COMPANY
ARTERIAL VASCULAR ENGINEERING UK LIMITED
COVIDIEN AG
Covidien Group S.a.r.l
COVIDIEN PRIVATE LIMITED
MDT TURKEY FINANSAL DANISMANLIK LIMITED SIRKETI
Medical Education Y.K.
MEDTRONIC AUDORA PTY LTD

Key people

Executive Chairman of the Board · since 2020
Carol A. Surface
Chief Human Resource Officer, Senior Vice President · since 2015
Hooman C. Hakami
Executive Vice President and Group President of the Diabetes Group · since 2015
Robert ten Hoedt
Executive Vice President and President - EMEAC · since 2015
Executive Vice President and President of Medtronic�s Minimally Invasive Therapies Group · since 2017
Senior Vice President and Chief Scientific, Clinical and Regulatory Officer · since 2015
Sally Saba
Chief Inclusion and Diversity Officer · since 2020
Senior Vice President, General Counsel, Corporate secretary · since 2015
Geoffrey S. Martha
President, Chief Executive Officer, Director · since 2020
Richard H. Anderson
Lead Independent Director · since 2015
Independent Director · since 2015
Independent Director · since 2019
Randall J. Hogan
Independent Director · since 2015
Independent Director · since 2011
Independent Director · since 2000
Kendall J. Powell
Independent Director · since 2015
IPO date
Nov 21, 1977
Employees
95,000
Domiciled in
IE
Incorporated in
IE
Legal address
Principal Executive Office Suite
Building 2
Parkmore Business Park West
Galway, D D02 XH02
IE
Headquarters
20 LOWER HATCH STREET
DUBLIN 2
DUBLIN, D D02 XH02
IE
Previous name
KALANI I LIMITED
Previous name
MEDTRONIC HOLDINGS LIMITED
Previous name
MEDTRONIC LIMITED

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFYFYFYFYFYFY
2026‑042025‑042025‑042024‑042024‑042023‑042023‑042022‑042022‑042021‑042020‑042020‑042019‑042019‑042018‑042018‑042017‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT